Lonafarnib - CAS# 193275-84-2 702 2014 May-Jun

2014 May-Jun

Treatment with OTS514 suppressed forkhead box protein M1 (FOXM1) activity

reduces Phospholipase A2 (PLA2) activity and sPLA2-IIA mRNA expression and mitigates LPS-induced lung injury by increasing increased Clara cell secretory protein (CCSP) expression

1380548-02-6

is potentially for the treatment of malaria

Lonafarnib - CAS# 193275-84-2 702 2014 May-JunLonafarnib is a farnesyl transferase inhibitor. Structurely, it is also a synthetic tricyclic derivative of carboxamide with antineoplastic properties. Lonarfanib binds to and inhibits farnesyl transferase, an enzyme involved in the post translational modification and activation of Ras proteins. Ras proteins participate in numerous signalling pathways (proliferation, cytoskeletal organization), and play an important role in oncogenesis. Mutated ras